Artal Group’s CRISPR Therapeutics CRSP Stock Holding History

Artal Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100,000	Closed	-$4.71M	–	105
2019 Q2	$4.71M	Sell	100,000 -45,000	-31%	-$1.8M	0.19%	81
2019 Q1	$5.18M	Hold	145,000	–	–	0.21%	72
2018 Q4	$4.14M	Buy	145,000 +45,000	+45%	+$1.56M	0.15%	73
2018 Q3	$4.43M	Buy	100,000 +50,000	+100%	+$2.62M	0.12%	78
2018 Q2	$2.94M	Buy	50,000 +25,000	+100%	+$1.42M	0.06%	86
2018 Q1	$1.14M	Sell	25,000 -25,000	-50%	-$1.03M	0.01%	102
2017 Q4	$1.17M	Buy	+50,000	New	+$950K	0.02%	109

Other funds holding CRSP

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Artal Group's CRSP Position: Q3 2019 in Review

Artal Group sold out of CRISPR Therapeutics (CRSP) in Q3 2019, closing a stake of 100,000 shares — an estimated $4.71M sold.

Artal Group first reported a position in CRSP in Q4 2017 and held it in 7 quarters. The position peaked at $5.18M in Q1 2019. 182 funds tracked by Wall St. Rank hold CRSP as of Q3 2019.

Artal Group reported no remaining CRISPR Therapeutics position as of Q3 2019 after selling out during the quarter.
Artal Group sold 100,000 CRISPR Therapeutics shares in Q3 2019, an estimated $4.71M.
Artal Group first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 7 quarters.
Artal Group's CRISPR Therapeutics position peaked at $5.18M in Q1 2019.
182 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2019.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.